Preop Lab Values May ID Risk of Postarthroplasty Joint Infection in Morbid Obesity
By Lori Solomon HealthDay Reporter
THURSDAY, July 25, 2024 -- Certain preoperative laboratory values may predict risk of periprosthetic joint infection (PJI) among individuals with morbid obesity undergoing arthroplasty, according to a study published in the July 17 issue of the Journal of Bone & Joint Surgery.
Sagar Telang, from the University of Southern California in Los Angeles, and colleagues sought to identify preoperative laboratory values that may serve as predictors of PJI in patients with morbid obesity undergoing total hip arthroplasty or total knee arthroplasty (TKA). Analysis included 6,780 patients (TKA: 76.7 percent) of whom 47 (0.69 percent) developed PJI within 90 days after surgery.
The researchers found that the rate of PJI was 1.69 percent for patients with a hemoglobin level of <12 g/dL (for females) or <13 g/dL (for males), 2.14 percent for those with a platelet count of <142,000/µL or >417,000/µL, 1.11 percent for those with a neutrophil-lymphocyte ratio (NLR) of >3.31, 1.69 percent for those with a platelet-lymphocyte ratio (PLR) of >182.3, and 1.05 percent for those with a systemic immune-inflammation index (SII) of >776.2. In adjusted analysis, there were significant associations between PJI and an abnormal preoperative NLR (adjusted odds ratio [aOR], 2.38), PLR (aOR, 4.86), SII (aOR, 2.44), platelet count (aOR, 3.50), and hemoglobin level (aOR, 2.62).
"These findings may help surgeons risk-stratify this high-risk patient population," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2024
Read this next
Prevalence of Extremely Severe Obesity Increasing in Children
TUESDAY, July 22, 2025 -- From 2008 to 2023, there was an increase in the prevalence of extremely severe obesity in children, especially among older adolescents and non-Hispanic...
Presurgical Immunotherapy Offers Long-Term Benefit in Melanoma
FRIDAY, July 18, 2025 -- Neoadjuvant systemic treatment (NST) followed by adjuvant treatment with nivolumab and relatlimab offers long-term benefit in adults with stage III/IV...
Long-Term Obesity Linked to Expression of Aging Biomarkers
THURSDAY, July 17, 2025 -- Long-term obesity is associated with the expression of biomarkers denoting antagonistic and integrative aging hallmarks in adults aged 28 to 31 years...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.